PRIMARY CARDIOPLOGY TRAINING GROUP

BUCARAMANGA HEART INSTITUTE

STUDENT: KAREN DANIELA BAUTISTA ESQUIVIA

CODE: 01210021064

TEACHER
LIDY HIGUERA

UNIVERSITY OF SANTANDER
UDES

2024
PRIMARY CARDIOPLOGY
TRAINING GROUP

BUCARAMANGA HEART INSTITUTE

WHAT IS CARDIOPLOGY?
Cardioplegia is a solution for intracardiac perfusion, it is used in combination with
ischemia, in order to induce cardiac arrest during heart surgery with CPB, with it we
protect the myocardium from the deleterious effects derived from the period of
ischemia and prevent the perfusion damage once blood flow is established.

MEMBERS CARDIOPLOGY IS DIVIDED INTO

INTRACELLULAR CARDIOPGY:
The cardiovascular surgeon
The anaesthesiologist Stops the heart in diastole through
The two chief nurses Na+ depletion
extracellular (membrane
The chief perfusionist
hyperpolarization-inhibits rapid
The nursing assistants depolarization phase)
The physician assistant
The surgical instrumentator EXTRACELLULAR CARDIOPGY:

Diastolic cessation occurs by

depolarization of the membrane due to
high concentrations of K+ (8-30 meq)

TYPES OF CARDIOPLOGY USED IN THE

INSTITUTION CUSTODIOL INDICATIONS
Custodiol, Del nido and
sanguine, but in the institution Patients with reduced
Custodiol is used more injection fraction
Aortic surgeries (bentall,
CUSTODIOL: The patient is dissections)
administered an initial dose of Patients with renal failure
1,000 cc. After the stipulated Technically complex
time of the initial dose, a procedures, where prolonged
maintenance dose is field times are expected
administered that would be half (double valve replacement)
the initial dose for 90 - 120 min. In redo

STATISTICS
Patients who
had problems
TOTAL
PATIENTS 58 with 8 DIED 1
cardioplegia

CONCLUSIONS
The administration of custodiol in
patients continues as it has been
doing, with the indication of no more
than 2,000cc.

Nido cardioplegia will be performed

only in patients who require it until
there are investigations with favorable
scientific results.

Follow-up statistics will continue for

patients with cardioplegia supplies.

Primary group meeting again in 1

year with new advances and evidence